Literature DB >> 2476080

Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin.

A P Lavrijsen1, L M Tieben, M Ponec, J G van der Schroeff, G N van Muijen.   

Abstract

The distribution of several markers of keratinocyte differentiation was studied in normal epidermis, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs) using the immunoperoxidase technique on frozen sections of punch biopsy specimens. As markers a panel of chain-specific monoclonal antibodies (MoAbs) directed against cytokeratin (CK) 4, 8, 10, 13, 18 and 19, a polyclonal antiserum against involucrin, as well as a MoAb against the epidermal growth factor (EGF) receptor were used. In 15 out of 19 BCCs tested, expression of CK 8 was seen. Only a few individual cells in a limited number of BCCs showed positive staining for CK 4, 18, or 19. No expression of CK 10 was seen except for some foci of cell keratinization. Involucrin was not found in BCCs except for some squamous horn cysts. In all BCC cells expression of EGF receptor was found. In the suprabasal layers of normal epidermis from SCC patients, positive staining for CK 10 was seen. A few individual cells in a limited number of SCCs showed positive staining for CK 4, 8, or 18. Involucrin was expressed in the center of SCCs and in the upper layers of normal epidermis. Expression of EGF receptor was found in all SCC cells. These results demonstrate differences in cellular origin and differentiation between BCC and SCC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476080     DOI: 10.1007/bf00426583

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  31 in total

1.  Enzyme-labeled antibodies: preparation and application for the localization of antigens.

Authors:  P K Nakane; G B Pierce
Journal:  J Histochem Cytochem       Date:  1966-12       Impact factor: 2.479

2.  Differentiation-related changes of cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult epidermis.

Authors:  G N Van Muijen; S O Warnaar; M Ponec
Journal:  Exp Cell Res       Date:  1987-08       Impact factor: 3.905

3.  Coexpression of intermediate filament polypeptides in human fetal and adult tissues.

Authors:  G N Van Muijen; D J Ruiter; S O Warnaar
Journal:  Lab Invest       Date:  1987-10       Impact factor: 5.662

4.  Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition.

Authors:  M R Green; J R Couchman
Journal:  J Invest Dermatol       Date:  1985-09       Impact factor: 8.551

5.  Keratoacanthoma and squamous cell carcinoma of the skin: immunohistochemical localization of involucrin and keratin proteins.

Authors:  B R Smoller; T H Kwan; J W Said; S Banks-Schlegel
Journal:  J Am Acad Dermatol       Date:  1986-02       Impact factor: 11.527

6.  Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies.

Authors:  E Debus; R Moll; W W Franke; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1984-01       Impact factor: 4.307

7.  Epidermal growth factor receptor expression related to differentiation capacity in normal and transformed keratinocytes.

Authors:  J Boonstra; S W De Laat; M Ponec
Journal:  Exp Cell Res       Date:  1985-12       Impact factor: 3.905

8.  Visualization of epidermal growth factor receptors in human epidermis.

Authors:  L B Nanney; J A McKanna; C M Stoscheck; G Carpenter; L E King
Journal:  J Invest Dermatol       Date:  1984-02       Impact factor: 8.551

Review 9.  Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview.

Authors:  F C Ramaekers; J J Puts; O Moesker; A Kant; A Huysmans; D Haag; P H Jap; C J Herman; G P Vooijs
Journal:  Histochem J       Date:  1983-07

10.  Tissue distribution of keratin 7 as monitored by a monoclonal antibody.

Authors:  F Ramaekers; A Huysmans; G Schaart; O Moesker; P Vooijs
Journal:  Exp Cell Res       Date:  1987-05       Impact factor: 3.905

View more
  7 in total

1.  Keratin specificity analyses of eight anti-keratin monoclonal antibodies, and their immunostaining patterns in normal skin using formalin-fixed and paraffin-embedded tissue specimens.

Authors:  S I Ansai; Y Katagata; K I Yoshikawa; Y Hozumi; K Aso
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

2.  Characterization of keratin peptide in sebaceous carcinomas.

Authors:  K Yoshikawa; Y Katagata; S Kondo
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

3.  The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells.

Authors:  E B van Dorst; G N van Muijen; S V Litvinov; G J Fleuren
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

4.  EGFR expression in advanced head and neck cutaneous squamous cell carcinoma.

Authors:  Larissa Sweeny; Nichole R Dean; J Scott Magnuson; William R Carroll; Emily E Helman; Stephen O Hyde; Renee L Desmond; Eben L Rosenthal
Journal:  Head Neck       Date:  2011-07-07       Impact factor: 3.147

5.  Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.

Authors:  Kaoru Kiguchi; Takuya Kitamura; Tricia Moore; Mohammad Rumi; Hsiang-Chun Chang; Devon Treece; Lynnsie Ruffino; Kevin Connolly; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-03

Review 6.  A review of intermediate filament biology and their use in pathologic diagnosis.

Authors:  R B Nagle
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

Review 7.  Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.

Authors:  Priscila Oliveira de Lima; Shannon Joseph; Benedict Panizza; Fiona Simpson
Journal:  Curr Treat Options Oncol       Date:  2020-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.